» Articles » PMID: 37607754

Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease

Overview
Specialty Neurology
Date 2023 Aug 22
PMID 37607754
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Anti-IgLON5 disease (IgLON5-D) may present with a bulbar-onset motor neuron disease-like phenotype, mimicking bulbar-onset amyotrophic lateral sclerosis. Recognition of their distinctive clinical and paraclinical features may help for differential diagnosis. We report 2 cases of atypical trigeminal neuropathy in bulbar-onset IgLON5-D.

Methods: Trigeminal nerve involvement was assessed using comprehensive clinical, laboratory, electrophysiologic, and MRI workup.

Results: Both patients were referred for progressive dysphagia, sialorrhea, and hoarseness. They were treated with bilevel positive airway pressure for nocturnal hypoventilation. Patient 1 complained of continuous facial burning pain with allodynia, exacerbated by mastication and prolonged speech. Patient 2 reported no facial pain. Anti-IgLON5 autoantibodies (IgLON5-Abs) were positive in serum for both patients and CSF for patient 1. Cerebral MRI revealed bilateral T2 fluid-attenuated inversion recovery (FLAIR) hyperintensity and enlargement of trigeminal nerves without gadolinium enhancement in both patients. Needle myography showed fasciculations in masseter muscles. Blink-reflex study confirmed bilateral trigeminal neuropathy only in patient 2. Cortical laser-evoked potentials showed a bilateral small-fiber dysfunction in the trigeminal nerve ophthalmic branch in patient 1.

Discussion: In case of progressive atypical bulbar symptoms, the presence of a trigeminal neuropathy or trigeminal nerve abnormalities on MRI should encourage the testing of IgLON5-Abs in serum and CSF.

Citing Articles

Papillitis associated with IgLON5 autoimmunity: A novel clinical phenotype.

Li X, Chen J, Hur M, Paton G, McKeon A, Zekeridou A J Neuroimmunol. 2024; 388:578312.

PMID: 38364528 PMC: 11152446. DOI: 10.1016/j.jneuroim.2024.578312.


.

de Carvalho M, Swash M Clin Neurophysiol Pract. 2024; 9:27-38.

PMID: 38249779 PMC: 10796809. DOI: 10.1016/j.cnp.2023.12.003.

References
1.
Gruter T, Mollers F, Tietz A, Dargvainiene J, Melzer N, Heidbreder A . Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease. Brain. 2022; 146(2):600-611. DOI: 10.1093/brain/awac090. View

2.
Shambrook P, Hesters A, Marois C, Zemba D, Servan J, Gaymard B . Delayed Benefit From Aggressive Immunotherapy in Waxing and Waning Anti-IgLON5 Disease. Neurol Neuroimmunol Neuroinflamm. 2021; 8(4). PMC: 8192057. DOI: 10.1212/NXI.0000000000001009. View

3.
Gaig C, Graus F, Compta Y, Hogl B, Bataller L, Bruggemann N . Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017; 88(18):1736-1743. PMC: 5409845. DOI: 10.1212/WNL.0000000000003887. View

4.
Sabater L, Planaguma J, Dalmau J, Graus F . Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation. 2016; 13(1):226. PMC: 5007989. DOI: 10.1186/s12974-016-0689-1. View

5.
Aghelan Z, Karima S, Ghadami M, Khazaie H, Bahrehmand F, Vaisi-Raygani A . IgLON5 autoimmunity tested positive in patients with isolated chronic insomnia disease. Clin Exp Immunol. 2022; 207(2):237-240. PMC: 8982976. DOI: 10.1093/cei/uxab017. View